Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185


Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.

Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, Monreal M, de Tute R, Vergilio JA, Rawstron AC, Paiva B.

Cytometry B Clin Cytom. 2016 Jan;90(1):31-9. doi: 10.1002/cyto.b.21228. Epub 2015 Jun 2.


Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.

Stetler-Stevenson M, Paiva B, Stoolman L, Lin P, Jorgensen JL, Orfao A, Van Dongen J, Rawstron AC.

Cytometry B Clin Cytom. 2016 Jan;90(1):26-30. doi: 10.1002/cyto.b.21249. Epub 2015 Jul 6.


Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.

Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, van Dongen JJ, Orfao A.

Cytometry B Clin Cytom. 2016 Jan;90(1):61-72. doi: 10.1002/cyto.b.21265. Epub 2015 Jul 31. Review.


Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.

Oldaker TA, Wallace PK, Barnett D.

Cytometry B Clin Cytom. 2016 Jan;90(1):40-6. doi: 10.1002/cyto.b.21276. Epub 2015 Sep 4.


Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.

Gormley NJ, Turley DM, Dickey JS, Farrell AT, Reaman GH, Stafford E, Carrington L, Marti GE.

Cytometry B Clin Cytom. 2016 Jan;90(1):73-80. doi: 10.1002/cyto.b.21268. Epub 2015 Jul 25.


Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.

Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, Kovarova L, Lioznov M, Mateo G, Morilla R, Mylin AK, Omedé P, Pellat-Deceunynck C, Perez Andres M, Petrucci M, Ruggeri M, Rymkiewicz G, Schmitz A, Schreder M, Seynaeve C, Spacek M, de Tute RM, Van Valckenborgh E, Weston-Bell N, Owen RG, San Miguel JF, Sonneveld P, Johnsen HE; European Myeloma Network.

Haematologica. 2008 Mar;93(3):431-8. doi: 10.3324/haematol.11080. Epub 2008 Feb 11.


Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service.

Rawstron AC, de Tute RM, Haughton J, Owen RG.

Cytometry B Clin Cytom. 2016 Jan;90(1):54-60. doi: 10.1002/cyto.b.21271. Epub 2015 Dec 21. Review.


Assessment of minimal residual disease in myeloma and the need for a consensus approach.

Rawstron AC, Paiva B, Stetler-Stevenson M.

Cytometry B Clin Cytom. 2016 Jan;90(1):21-5. doi: 10.1002/cyto.b.21272. Epub 2015 Sep 23.


Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry.

Wood BL.

Cytometry B Clin Cytom. 2016 Jan;90(1):47-53. doi: 10.1002/cyto.b.21239. Epub 2015 May 29. Review.


Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy.

Mathis S, Chapuis N, Borgeot J, Maynadié M, Fontenay M, Béné MC, Guy J, Bardet V.

Cytometry B Clin Cytom. 2015 Mar;88(2):101-9. doi: 10.1002/cyto.b.21200. Epub 2014 Nov 17.


Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.

Muccio VE, Saraci E, Gilestro M, Gattei V, Zucchetto A, Astolfi M, Ruggeri M, Marzanati E, Passera R, Palumbo A, Boccadoro M, Omedè P.

Cytometry B Clin Cytom. 2016 Jan;90(1):81-90. doi: 10.1002/cyto.b.21279. Epub 2015 Sep 23.


Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease.

Preffer FI, Yuan CM, Lin P, Stetler-Stevenson M, Marti GE.

Cytometry B Clin Cytom. 2016 Jan;90(1):9-10. doi: 10.1002/cyto.b.21342. No abstract available.


Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.

Liu D, Lin P, Hu Y, Zhou Y, Tang G, Powers L, Medeiros LJ, Jorgensen JL, Wang SA.

J Clin Pathol. 2012 Sep;65(9):823-9. doi: 10.1136/jclinpath-2012-200881. Epub 2012 Jun 8.


Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.

Pojero F, Flores-Montero J, Sanoja L, Pérez JJ, Puig N, Paiva B, Bottcher S, van Dongen JJ, Orfao A; EuroFlow group.

Cytometry B Clin Cytom. 2016 Jan;90(1):91-100. doi: 10.1002/cyto.b.21269. Epub 2015 Jul 31.


Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.

Gupta R, Bhaskar A, Kumar L, Sharma A, Jain P.

Am J Clin Pathol. 2009 Nov;132(5):728-32. doi: 10.1309/AJCP1GYI7EHQYUYK.


[Comparison and analysis of minimal residual disease in multiple myeloma patients detected by 4-color and 8-color fluorescence antibody panels].

Wang YZ, Lu J, Hao L, Chang Y, He LL, Huang XJ, Liu YR.

Zhonghua Xue Ye Xue Za Zhi. 2017 Apr 14;38(4):272-278. doi: 10.3760/cma.j.issn.0253-2727.2017.04.003. Chinese.


A GEIL flow cytometry consensus proposal for quantification of plasma cells: application to differential diagnosis between MGUS and myeloma.

Frébet E, Abraham J, Geneviève F, Lepelley P, Daliphard S, Bardet V, Amsellem S, Guy J, Mullier F, Durrieu F, Venon MD, Leleu X, Jaccard A, Faucher JL, Béné MC, Feuillard J; GEIL Groupe d'Etude Immunologique des Leucémies Study Group.

Cytometry B Clin Cytom. 2011 May;80(3):176-85. doi: 10.1002/cyto.b.20581. Epub 2010 Dec 10.


Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program.

Keeney M, Halley JG, Rhoads DD, Ansari MQ, Kussick SJ, Karlon WJ, Mehta KU, Dorfman DM, Linden MA.

Arch Pathol Lab Med. 2015 Oct;139(10):1276-80. doi: 10.5858/arpa.2014-0543-CP. Epub 2015 Feb 19.


Supplemental Content

Support Center